The speaker develops RADARS, a programmable RNA-guided gene-delivery system that activates only in cells with specific RNA “fingerprints.” Their thesis tackles weak activation when target RNA is rare, creating new mechanisms to bind targets more tightly. These innovations aim to enable safer, cell-specific cancer therapies through precise molecular control.

This project develops an “Aptamer Express,” a DNA-based Trojan horse designed to bypass the brain’s protective barriers, target tumours, and deliver cancer-killing drugs directly to brain cancer cells. The approach aims to overcome treatment resistance, improve precision, and reduce side effects, offering new hope for patients and their families.

This research targets the earliest stage of allergic and asthmatic immune reactions by blocking key cytokine “messages” sent from T cells to B cells. Using drug-discovery techniques, the project identifies compounds that prevent immune overreaction before symptoms begin, aiming to develop a new class of long-lasting preventative allergy and asthma treatments.